Corbus Pharmaceuticals Holdings Inc (CRBP) is not a strong buy at the moment for a beginner investor with a long-term focus. While the stock has shown some positive momentum recently, the lack of significant financial growth, absence of recent news catalysts, and no strong trading signals make it prudent to hold off on investing until more robust data or developments emerge.

Technical Analysis

The MACD histogram is positive and expanding, indicating bullish momentum. However, the RSI is in the neutral zone at 71.256, and moving averages are bearish (SMA_200 > SMA_20 > SMA_5). The stock is trading near its resistance level (R2: 8.358), which may limit further upside in the short term.

Options Data

Bullish

Open Interest Put-Call Ratio

Bullish

Option Volume Put-Call Ratio

The low put-call ratios suggest a bullish sentiment in the options market, but the high implied volatility (199.68) indicates significant risk.

Technical Summary

Sell

Buy

Positive Catalysts

Analysts from RBC Capital have given an Outperform rating with a price target of $53, citing undervaluation and potential in its obesity and cancer drug pipeline. The stock has shown recent price momentum with a 6.18% regular market gain and a 2.83% pre-market gain.

Neutral/Negative Catalysts

The company's financials remain weak, with no revenue growth and negative net income (-$23.34M in Q3 2025). Insider and hedge fund trading activity is neutral, and there are no recent news catalysts or congress trading data to support a buy decision.

Financial Performance

In Q3 2025, the company reported no revenue growth (0% YoY) and a net income of -$23.34M, which improved by 69.35% YoY. EPS also improved to -1.9, up 65.22% YoY, but the company remains unprofitable.

Growth

Profitability

Efficiency

Analyst Ratings and Price Target Trends

RBC Capital has an Outperform rating with a price target of $53, citing undervaluation and potential in its drug pipeline. However, there is no consensus among analysts, and another analyst's price target and commentary were unrelated to CRBP.

8 Analyst Rating

Wall Street analysts forecast CRBP stock price to rise

8 Buy

0 Hold

0 Sell

Strong Buy

Current: 8.210

Low

Averages

46.71

High

Current: 8.210

Low

Averages

46.71

High

RBC Capital

Outperform

maintain

$53

AI Analysis

2025-12-11

Reason

RBC Capital

Price Target

$53

AI Analysis

2025-12-11

maintain

Outperform

Reason

RBC Capital notes that Corbus Pharmaceuticals has disclosed updates from its Phase I SAD/MAD study of CRB-913, a CB1 receptor inverse agonist, and management also hosted a conference call to discuss the data in detail. Early hints at efficacy and possibility Corbus could navigate a therapeutic window better than prior CB1 efforts should draw attention to this under-the-radar asset, with more robust de-risking data potentially only a few quarters away. At a $35M EV, with a cancer drug in '701 RBC views as low-risk, and a higher-risk but potentially very large-opportunity obesity asset, the firm believes the company is undervalued. The firm has an Outperform rating on the shares with a price target of $53.

Stifel

Stephen Willey

Buy

maintain

$28 -> $32

2025-12-04

Reason

Stifel

Stephen Willey

Price Target

$28 -> $32

2025-12-04

maintain

Buy

Reason

Stifel analyst Stephen Willey raised the firm's price target on Crescent Biopharma to $32 from $28 and keeps a Buy rating on the shares. The firm believes the Kelun deal creates "greater pipeline and CR-001 development and optionality," with Crescent "securing ex-Greater China rights to an ADC with a clinically-validated target antigen and linker/payload and positioning itself to leverage data generated from Kelun's interrogation of CR-001-based combinations with its other ADCs."

Unlock Full Analyst Thesis， Get the complete breakdown of rating reason for CRBP

Unlock Now

CRBP Should I Buy

CRBP Should I Buy

Should You Buy Corbus Pharmaceuticals Holdings Inc (CRBP) Today? Analysis, Price Targets, and 2026 Outlook.

Technical Analysis

Options Data

Technical Summary

Positive Catalysts

Neutral/Negative Catalysts

Financial Performance

Growth

Profitability

Efficiency

Analyst Ratings and Price Target Trends

People Also Watch